Jane Street Group LLC Makes New $295,000 Investment in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Jane Street Group LLC purchased a new position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 4,221 shares of the company’s stock, valued at approximately $295,000. Jane Street Group LLC owned about 0.10% of Invesco Biotechnology & Genome ETF at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. One Capital Management LLC lifted its stake in shares of Invesco Biotechnology & Genome ETF by 31.9% during the second quarter. One Capital Management LLC now owns 25,402 shares of the company’s stock worth $1,646,000 after buying an additional 6,137 shares during the period. Carnegie Investment Counsel acquired a new stake in shares of Invesco Biotechnology & Genome ETF during the third quarter worth $204,000. HighTower Advisors LLC lifted its stake in shares of Invesco Biotechnology & Genome ETF by 64.1% during the third quarter. HighTower Advisors LLC now owns 7,101 shares of the company’s stock worth $494,000 after buying an additional 2,774 shares during the period. IHT Wealth Management LLC lifted its stake in shares of Invesco Biotechnology & Genome ETF by 14.7% during the third quarter. IHT Wealth Management LLC now owns 12,124 shares of the company’s stock worth $847,000 after buying an additional 1,550 shares during the period. Finally, Massachusetts Wealth Management lifted its stake in shares of Invesco Biotechnology & Genome ETF by 7.3% during the third quarter. Massachusetts Wealth Management now owns 18,184 shares of the company’s stock worth $1,270,000 after buying an additional 1,240 shares during the period.

Invesco Biotechnology & Genome ETF Trading Down 1.5 %

NYSEARCA:PBE opened at $67.88 on Friday. Invesco Biotechnology & Genome ETF has a 12 month low of $59.32 and a 12 month high of $72.84. The firm has a fifty day simple moving average of $68.84 and a 200-day simple moving average of $68.89. The company has a market capitalization of $274.24 million, a P/E ratio of 17.12 and a beta of 0.88.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.